Clinico-genetic model to predict methotrexate intolerance in rheumatoid arthritis

ConclusionsA clinical-genetic model including BMI and SNP FPGS 10101 was found to have a modest prediction ability for methotrexate intolerance.Key Points•Methotrexate intolerance (symptomatic adverse effects) was common and occurred in 37% patients over 6  months.•SNP FPGS rs10106 and low body mass index were associated with methotrexate intolerance.•Clinico-genetic model had a modest ability of 66% for predicting intolerance.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research